| Serial Number | 77937687 |
| Word Mark | ARK THERAPEUTICS |
| Filing Date | Wednesday, February 17, 2010 |
| Status | 710 - CANCELLED - SECTION 8 |
| Status Date | Friday, March 8, 2019 |
| Registration Number | 4184675 |
| Registration Date | Tuesday, August 7, 2012 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 3, 2012 |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Disclaimer with Predetermined Text | "THERAPEUTICS" |
| Goods and Services | Diagnostic protein preparations for use in science, scientific diagnostics, medical laboratory use and research; diagnostic preparations of genes for use in science, scientific diagnostics, medical laboratory use and research |
| Goods and Services | Diagnostic protein preparations for medical use; diagnostic preparations of genes for medical use; pharmaceutical preparations for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; pharmaceutical preparations for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; pharmaceutical preparations to promote or suppress angiogenesis and enhance blood flow; pharmaceutical preparations for increasing the efficiency of muscle cell energy production; therapeutic agents for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; therapeutic agents for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; therapeutic agents to promote or suppress angiogenesis and enhance blood flow; therapeutic agents for increasing the efficiency of muscle cell energy production; diagnostic preparations for medical purposes; protein preparations for clinical or medical laboratory use, namely, for targeting therapeutic agents to specific sites; medical dressings; surgical dressings; burn dressings; wound dressings; absorbent wound and burn dressings in the nature of pads; foot and hand dressings for medical purposes; fluid handling foot and hand dressings for medical purposes; preparations of genes for therapeutic purposes, namely, for the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting; preparations of genes for therapeutic purposes, namely, for the prevention of stenosis, namely, stenosis caused by intimal hyperplasia following surgical procedures; preparations of genes for therapeutic purposes, namely, to promote or suppress angiogenesis and enhance blood flow; preparations of genes for therapeutic purposes, namely, for increasing the efficiency of muscle cell energy production; foot and hand dressings for medical purposes, namely, for the treatment of wounds and burns; none of the above including dietary and nutritional supplements |
| Goods and Services | Boots and gloves for orthopaedic and medical purposes; parts of boots and gloves for orthopedic and medical purposes, namely, heels, soles and inserts; boots and gloves for medical purposes with the ability to handle wound fluid; boots and gloves for medical use and absorbent filters, liners and inserts for use therewith; filters, soles and absorbent inserts for boots and gloves for medical purposes, namely, for the treatment of wounds and burns; biodegradable collagen collar delivery devices for delivering therapeutic agents and gene therapy products to specific sites |
| Goods and Services | Scientific, medical and clinical research, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; providing scientific, medical and clinical research information, all in the field of the treatment of wounds, burns, vascular and circulatory system related diseases, cancer, malignant glioma and other malignant brain tumors, macular degeneration, lipodystrophy and other metabolic conditions associated with the use of anti-HIV therapy, cachexia and muscle wasting, prevention of stenosis, increasing the efficiency of muscle cell energy production and promoting or suppressing angiogenesis and enhancing blood flow; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances; scientific, medical and clinical research in the field of gene therapy; scientific, medical and clinical research for the discovery, design, creation, development and testing in the field of pharmaceutical preparations and therapeutically active substances for use in the field of gene therapy; scientific, medical and clinical research in the field of genes and genetics; medical and scientific research, namely, conducting gene therapy trials; none of the above in the dietary or nutritional supplement field |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, March 8, 2019 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, March 8, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, March 8, 2019 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, March 8, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Ark Therapeutics Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 03 - Corporation |
| Address | London, W1W 6XB GB |
| Party Name | Ark Therapeutics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | London, W1W 6XB GB |
| Party Name | Ark Therapeutics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | London, W1W 6XB GB |
| Event Date | Event Description |
| Friday, March 8, 2019 | CANCELLED SEC. 8 (6-YR) |
| Monday, August 7, 2017 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Tuesday, August 7, 2012 | REGISTERED-PRINCIPAL REGISTER |
| Thursday, June 28, 2012 | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |
| Thursday, June 28, 2012 | NOTICE OF ALLOWANCE CANCELLED |
| Thursday, June 28, 2012 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Friday, June 22, 2012 | TEAS DELETE 1(B) BASIS RECEIVED |
| Tuesday, May 29, 2012 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, April 3, 2012 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 3, 2012 | PUBLISHED FOR OPPOSITION |
| Wednesday, March 14, 2012 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, February 27, 2012 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Tuesday, February 21, 2012 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, February 10, 2012 | EXAMINER'S AMENDMENT ENTERED |
| Friday, February 10, 2012 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, February 10, 2012 | EXAMINERS AMENDMENT E-MAILED |
| Friday, February 10, 2012 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, February 1, 2012 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, February 1, 2012 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, January 10, 2012 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, July 12, 2011 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, July 12, 2011 | NON-FINAL ACTION E-MAILED |
| Tuesday, July 12, 2011 | NON-FINAL ACTION WRITTEN |
| Tuesday, June 21, 2011 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, June 21, 2011 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, June 15, 2011 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Tuesday, December 21, 2010 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Tuesday, December 21, 2010 | NON-FINAL ACTION E-MAILED |
| Tuesday, December 21, 2010 | NON-FINAL ACTION WRITTEN |
| Tuesday, November 30, 2010 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, November 30, 2010 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, November 29, 2010 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 27, 2010 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 27, 2010 | NON-FINAL ACTION E-MAILED |
| Thursday, May 27, 2010 | NON-FINAL ACTION WRITTEN |
| Thursday, May 20, 2010 | ASSIGNED TO EXAMINER |
| Friday, April 9, 2010 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Thursday, April 8, 2010 | ASSIGNED TO LIE |
| Monday, March 29, 2010 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Tuesday, February 23, 2010 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Saturday, February 20, 2010 | NEW APPLICATION ENTERED IN TRAM |